Payment overview · 2025
General Payments
$7,803.04
88 reported records · 11 companies
Healthcare provider profile · identity verified
Edward Ralph Assi, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · EL PASO, TX · NPI 1669472544
Verified facts
What the public records show
CMS Open Payments records show Edward Ralph Assi, D.O. received $7,803.04 in general payments during 2025 across 88 reported records.
Medtronic, Inc. accounted for 44.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$3,473.59 | 44.5% | 45 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $2,696.07 | 34.5% | 16 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $602.82 | 7.7% | 11 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $410.33 | 5.3% | 7 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $249.84 | 3.2% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $100.00 | 1.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $99.02 | 1.3% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $75.67 | 1.0% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $62.62 | 0.8% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $18.13 | 0.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.95 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,035.33 | 71 |
| Travel and Lodging | $3,767.71 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VersaCross Access Solution Normalized: versacross access solution |
Device | Boston Scientific Corporation | $2,559.56 | 13 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $1,161.77 | 15 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $534.64 | 10 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $249.84 | 3 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $223.85 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $223.85 | 2 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $167.65 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $167.36 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $112.92 | 1 | 2025 |
Source payment records
|
|||||
| LM Undivided Normalized: lm undivided |
Device | Philips North America LLC | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $99.02 | 1 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $89.13 | 3 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $83.22 | 2 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $75.67 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $62.62 | 1 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $46.47 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $23.59 | 2 | 2025 |
Source payment records
|
|||||
| PLASMABLADE(TM) Normalized: plasmablade tm |
Device | Medtronic, Inc. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $19.12 | 3 | 2025 |
Source payment records
|
|||||
| AQUAMANTYS(TM) Normalized: aquamantys tm |
Device | Medtronic, Inc. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| RADIALUX Normalized: radialux |
Device | Medtronic, Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 91 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
59 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
91 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 896 | 339 |
| Atorvastatin Calcium | Atorvastatin Calcium | 877 | 308 |
| Losartan Potassium | Losartan Potassium | 725 | 276 |
| Amlodipine Besylate | Amlodipine Besylate | 695 | 267 |
| Carvedilol | Carvedilol | 647 | 242 |
| Eliquis | Apixaban | 613 | 190 |
| Lisinopril | Lisinopril | 371 | 136 |
| Clopidogrel | Clopidogrel Bisulfate | 366 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 366 | 130 |
| Spironolactone | Spironolactone | 353 | 125 |
| Furosemide | Furosemide | 224 | 86 |
| Xarelto | Rivaroxaban | 219 | 70 |
| Chlorthalidone | Chlorthalidone | 187 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 67 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 170 | 57 |
| Nifedipine Er | Nifedipine | 158 | 58 |
| Entresto | Sacubitril/Valsartan | 156 | 46 |
| Warfarin Sodium | Warfarin Sodium | 136 | 42 |
| Ezetimibe | Ezetimibe | 134 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 48 |
| Amiodarone Hcl | Amiodarone Hcl | 121 | 57 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 99 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 38 |
| Farxiga | Dapagliflozin Propanediol | 91 | 28 |
| Flecainide Acetate | Flecainide Acetate | 91 | 32 |
| Ranolazine Er | Ranolazine | 88 | 37 |
| Potassium Chloride | Potassium Chloride | 78 | 28 |
| Cilostazol | Cilostazol | 76 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 75 | 28 |
| Simvastatin | Simvastatin | 71 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 65 | 19 |
| Repatha Sureclick | Evolocumab | 61 | 15 |
| Brilinta | Ticagrelor | 59 | 22 |
| Clonidine Hcl | Clonidine Hcl | 41 | 12 |
| Nitroglycerin | Nitroglycerin | 40 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 14 |
| Sotalol | Sotalol Hcl | 39 | 17 |
| Digoxin | Digoxin | 33 | 15 |
| Propafenone Hcl | Propafenone Hcl | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 13 |
| Midodrine Hcl | Midodrine Hcl | 28 | 14 |
| Valsartan | Valsartan | 27 | 11 |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Multaq | Dronedarone Hcl | 17 | suppressed |
| Famotidine | Famotidine | 16 | 11 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Prednisone | Prednisone | 14 | 12 |
| Telmisartan | Telmisartan | 14 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Corlanor | Ivabradine Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,803.04 · 88 records | Medtronic, Inc. | AQUAMANTYS(TM), ARTIX MT, AZURE XT DR MRI SURESCAN, COBALT DR MRI SURESCAN, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, FARXIGA, FFRct, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, General - Vascular Intervention, INSPIRE, LINQ II, LM Undivided, LifeVest, MICRA, ONYX FRONTIER, PLASMABLADE(TM), RADIALUX, RUBY Coil, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VersaCross Access Solution, WATCHMAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error